PCVX
Vaxcyte, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 12 to May 13 ▲ 2 buys: Gilbert Cisneros bought $1,001 - $15,000, last disclosed Jun 9
- Aug 3 to Aug 5 ▼ 2 days of insider sells: $1.6M by 3 insiders, avg $54.53
- Sep 1 to Sep 9 ▼ 3 days of insider sells: $376.2K by 1 insider, avg $60.76
- Oct 1 to Oct 5 ▼ 2 days of insider sells: $3.3M by 2 insiders, avg $85.02
- Oct 4 Vaxcyte announced it will host a webcast on October 5, 2026 to prese…
- Oct 8 ▼ Vaxcyte is raising $500M (up to $575M with overallotment) via 1.50%…
- Oct 8 ▼ Vaxcyte is raising ~$474M in a common stock and pre-funded warrant o…
- Oct 9 ▼ Vaxcyte entered into a First Supplemental Indenture to issue $575M a…
- Oct 16 Trial readout: Results Pending: 31 valent pneumococcal conjugate vaccine…
- Nov 2 ▼ 2 insiders sell $319.8K at $60.91
- Nov 11 ▼ 1 insider sell $1.2M at $67.83
- Nov 13 Trial readout: Results Pending: 31-valent pneumococcal conjugate vaccine…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $6.8M.
- InstitutionsMIXED
Q2 2026: 32 added (0 new), 29 trimmed or exited.
- AnalystsBULLISH
15 of 17 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$2.050 → −$1.907 over 90 days. 4 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +5.0% to 15.36M shares. 6.7 days to cover, ≈9.7% of shares.
- TrendDOWNTREND
1% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $1.2B |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $173.8M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | TRIM | $143.7M |
| D. E. Shaw & Co., Inc. | TRIM | $110.6M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | $69.4M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | $51.2M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | $45.5M |
| UBS Group AG | TRIM | $45.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +96%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald REITERATE | Overweight |
| Oct 5, 2026 | BTIG REITERATE | Buy |
| Oct 5, 2026 | Needham MAINTAIN | Buy |
| Oct 5, 2026 | Guggenheim MAINTAIN | Buy |
| Sep 28, 2026 | B of A Securities MAINTAIN | Buy |
| Sep 25, 2026 | Needham REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Dhaliwal Harpreet S. Chief Technical Ops Officer Nov 11, 2026 | EXERCISE | $421.4K |
Dhaliwal Harpreet S. Chief Technical Ops Officer Nov 11, 2026 | SELL | $480.4K |
Dhaliwal Harpreet S. Chief Technical Ops Officer Nov 11, 2026 | SELL | $636.9K |
Dhaliwal Harpreet S. Chief Technical Ops Officer Nov 11, 2026 | SELL | $35.8K |
Cowan Elvia SVP, Finance & CAO Nov 2, 2026 | SELL | $146.7K |
Cowan Elvia SVP, Finance & CAO Nov 2, 2026 | EXERCISE | $77.8K |
Wassil Jim EVP, Chief Scientific Ofc, COO Nov 2, 2026 | SELL | $21.1K |
Cowan Elvia SVP, Finance & CAO Nov 2, 2026 | SELL | $36.1K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.91 | -$2.35–-$1.31 | +15.2% | $0.00 |
| Next Q | -$1.51 | -$2.00–-$0.97 | -14.1% | $0.00 |
| Current FY | -$7.86 | -$8.62–-$7.18 | +7.9% | $0.00 |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
25 filings · 4 press releases · 1 bullish · 5 bearish · 19 neutral- NEUTRAL SC 13GNov 16, 2026
Wellington Management Group LLP filed a Schedule 13G disclosing a 5.2% passive stake in Vaxcyte as of September 30, 2026, representing 7,733,961 shares. This is a new filing by Wellington, adding to recent accumulation by other large institutional holders like T. Rowe Price (11.6%) following…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Harpreet S. Dhaliwal, an officer of Vaxcyte, filed a Form 144 notice of intent to sell 17,000…
The sale is small relative to market cap and likely part of routine option exercise and tax-related selling. Monitor for any subsequent Form 4 filings to confirm execution and any larger insider…
- NEUTRAL SC 13G/ANov 6, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing an 11.6% passive…
The increased passive stake signals continued institutional confidence but does not imply activist intent. Monitor for any future conversion to a 13D filing, which would indicate a shift to active…
- NEUTRAL SC 13G/ANov 6, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 9.6% passive stake…
Monitor whether T. Rowe Price files a 13D (activist conversion) or continues to adjust its position in future 13G amendments. The passive nature of this filing suggests no imminent activist intent.
All PCVX filing & press-release reports (29)
- SC 13G reportNov 16, 2026
- 144 reportNov 12, 2026
- SC 13G/A reportNov 6, 2026
- SC 13G/A reportNov 6, 2026
- CLUSTER reportNov 4, 2026
- 8-K reportNov 4, 2026
- 144 reportNov 2, 2026
- 144 reportNov 2, 2026
- 8-K reportOct 9, 2026
- 424B5 reportOct 8, 2026
- 424B5 reportOct 8, 2026
- 424B5 reportOct 5, 2026
- 424B5 reportOct 5, 2026
- 8-K reportOct 5, 2026
- PRESS-RELEASE reportOct 5, 2026
- PRESS-RELEASE reportOct 4, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportJul 6, 2026
- CLUSTER reportJul 6, 2026
- 144 reportJun 26, 2026
- 8-K reportJun 23, 2026
- CLUSTER reportJun 18, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 23, 2026
- CLUSTER reportApr 1, 2026
- PRESS-RELEASE reportMar 23, 2026
- 8-K reportFeb 24, 2026
- 8-K reportFeb 24, 2026